Divalproex Sodium Tablet, Delayed Release
Product Images NDC 55154-5633

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-5633). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (4fc50afb 67f3 4bf3 9ec3 Cc12734f47fd 00)

Label for Divalproex Sodium delayed-release tablets, 500 mg, USP with valproic acid activity. The unit dose package contains 10 tablets and includes storage instructions (20° to 25° C, protect from light), RX only status, and a pharmacist dispensing note. Manufactured by Upsher-Smith Laboratories, LLC and distributed by Cardinal Health.*

FDA Label Image

Chemical Structure (Divalproex 01)

Chemical structure of divalproex sodium, showing the molecular arrangement including two valproate units and a sodium ion within parentheses repeated n times.*

FDA Label Image

Figure 1 (Divalproex 02)

A bar chart comparing percentage results for placebo (PBO) and Divalproex Sodium (DVPX) groups across two studies labeled YMRS and MRS. The chart shows higher percentage values for DVPX (60% and 58%) compared to PBO (26% and 29%) in both studies, with percentages indicated above each bar.*

FDA Label Image

Figure 2 (Divalproex 03)

A line graph comparing the percentage reduction in CPS rate between Divalproex sodium and placebo. The x-axis represents the percentage of patients, while the y-axis shows the percent reduction in CPS rate, ranging from -100% (worsening) to 100% (improvement). The solid line denotes Divalproex sodium, and the dashed line indicates placebo, demonstrating greater CPS rate improvement with Divalproex sodium.*

FDA Label Image

Figure 3 (Divalproex 04)

A graph depicting the percentage reduction in CPS rate relative to the percentage of patients, comparing high dose (solid line) and low dose (dashed line) groups. The vertical axis measures improvement to worsening in CPS rate, while the horizontal axis shows the percentage of patients.*

FDA Label Image

Figure 4 (Divalproex 05)

A bar chart comparing two studies showing the effect of Divalproex Sodium versus placebo. Each study includes two bars: one for placebo and one for Divalproex Sodium, with numeric values on the vertical axis ranging from 0 to 6. The chart visually presents data from Study 1 and Study 2 for placebo and Divalproex Sodium groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.